Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients

Gucalp, Rasim; Lia, Salvatore; McKitrick, John C.; Wiernik, Peter H.

doi:10.1016/0002-9343(88)90172-6

Cited by 12 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies comparing the association of an aminoglycoside and an ureidopenicillin or a broad-spectrum cephalosporin have failed to show differences (5,9,13,18), except when the cephalosporin had low activity against Pseudomonas species (16).…”

Section: Resultsmentioning

confidence: 99%

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer

Feliú

Artal

Barón

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A total of 170 febrile episodes in neutropenic patients with cancer were randomly assigned to be treated with piperacillin-amikacin or ceftazidime-amikacin. The overall response rates were similar in both groups (68 and 65%, respectively). Response rates for clinicallBy or microbiologicaily documented episodes were 54.5% for piperacillin-amikacin and 58.8% for ceftazidime-amikacin. Response rates for gram-negative bacillary infections were 65 and 73%, respectively. There was also no difference for gram-positive infections (31 and 50%1, respectively). The toxicities were also comparable and consisted of skin rashes, hypokalemia, and diarrhea. Vancomycin was added if the fever persisted 72 h after the beginning of therapy, it increased the response rates to 94% when used with piperacillin-amikacin and 92% when used with ceftazidime plus amikacin. Our results suggest that the combinations show similar global efficacies in the treatment of febrile episodes in cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer

Feliú

Artal

Barón

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease

Wee¹

1993

Archives of Internal Medicine

View full text Add to dashboard Cite

The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis

Lucas

Brown

Armstrong

et al. 1996

Cancer

165

View full text Add to dashboard Cite

Children hospitalized for fever and neutropenia who have persistent fever and an ANC of less than 100 after 48 hours are at high risk for morbidity and are more likely to require antibiotic changes and antifungal therapy. Children who initially lack signs of sepsis, are afebrile, and have an ANC of 100 or higher after 48 hours are at low risk for complications and could be selectively discharged on antimicrobials after a 48-hour period of inpatient hospitalization.

show abstract

Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients

Cited by 12 publications

References 21 publications

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer

Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer

Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease

The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis

Contact Info

Product

Resources

About